NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for A431 Cells (Epidermoid Carcinoma Cells, CRL-1555)
Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Effective and robust intracellular delivery
Kit includes Transfection Enhancer reagent
Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
Work in the presence of serum
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download PowerPoint presentation for A431 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 81% transfection efficiency of siRNA delivery. Transfection efficiency was determined by real-time RT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems A431 Transfection Protocol: [PDF]
Download MSDS: [PDF]
A-431 Cell Line:
The A-431 cell line was established from the epidermis (skin) of an 85-year-old female patient who suffered from epidermoid carcinoma. These cells exhibit an epithelial morphology, and are tumorigenic. A-431 was established by D.J. Giard, et al. from solid tumors, along with many other cell lines. This cell line could be useful for studying of medical treatments and for research of certain types of skin cancer.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into A431 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in A431 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into A431 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):
- PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
- J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
- J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis … Zhang et al [PDF]
- Mol Cell Biol. 2013 33(7). SCO2 induces p53-mediated apoptosis by Thr845 phosphorylation … Madan et al [PDF]
- Hypertension. 2015 65(2):430-9. Neurokinin 3 receptor and phosphocholine transferase… Parchim et al [PDF]
- PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and preoptimized transfection kits, elecroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #1170)
- 1.5 ml (Catalog #1171)
- 1.5 ml CRISPR (Catalog #2103)
- 8.0 ml (Catalog #7020)